Lupin is currently trading at Rs. 816.45, up by 1.90 points or 0.23% from its previous closing of Rs. 814.55 on the BSE.
The scrip opened at Rs. 816.60 and has touched a high and low of Rs. 824.90 and Rs. 811.00 respectively. So far 143212 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1132.00 on 27-Jul-2017 and a 52 week low of Rs.723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 825.95 and Rs. 793.15 respectively. The current market cap of the company is Rs. 37044.91 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.89% and 15.10% respectively.
Lupin has launched Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Desoximetasone Topical Spray, 0.25% had annual sales of around $18.7 million in the US (IQVIA MAT May 2018).
Lupin's Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
